Login to Your Account



ImClone Stock Under Pressure

Abgenix Plans BLA Filing On Robust Panitumumab Results

By Karen Pihl-Carey


Friday, November 4, 2005
Abgenix Inc.'s stock surged 37.7 percent Thursday following news that its EGFr inhibitor, panitumumab, significantly improved progression-free survival in a pivotal metastatic colorectal cancer study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription